20 articles
A Phase 2 open-label trial explores whether an approved immune drug can raise frataxin protein levels and slow neurological decline in Friedreich Ataxia.
Cassava Sciences' 76-week Phase 3 trial of simufilam for Alzheimer's was terminated, raising questions about the drug's future.
24-week trial tested fucoxanthin-rich microalgae supplement on memory, attention, and executive function in 66 healthy seniors.
A completed Phase 1/2 pilot trial tested whether the senolytic duo D+Q penetrates the brain in early Alzheimer's disease.
A completed Phase 1 trial compared the abuse liability of rapastinel versus ketamine in recreational polydrug users, with implications for safer depression treatment.
32-person study explores how intermittent fasting affects blood vessel function and brain performance through protective pathways.
A completed Phase 4 trial from India evaluates whether ALA supplementation boosts flunarizine's migraine-prevention power in adolescents.
Italian researchers test plant-based compounds for brain health and quality of life in aging adults with promising early results.
A completed trial tests whether daily Nordic berry beverages can sharpen cognition in healthy adults over 12 weeks.
Study tests whether fasting before or after soccer heading reduces brain injury markers and cognitive impairment in college athletes.
A completed RCT tests whether treating insomnia with CBT-I can improve cognition and slow amyloid buildup in adults aged 60–85.
Clinical trial explores whether resetting gut microbiome through fecal transplants can slow Parkinson's progression and reduce symptoms.
Small trial tested whether fish oil and alpha lipoic acid could slow Alzheimer's by reducing oxidative stress markers in blood.
60-patient trial explores whether metformin, combined with standard therapy, could slow Parkinson's progression through metabolic pathways.
King's College study tests whether simple chewing and fasting patterns can enhance cognitive function and neurogenesis in older adults.
Contraloid acetate, an oral all-D-peptide designed to disassemble toxic amyloid-beta oligomers, completed its first-in-human safety trial in 40 healthy volunteers.
A phase 2/3 trial of the BACE inhibitor atabecestat in amyloid-positive asymptomatic adults was terminated before completion, raising questions about this drug class.
Probucol, a discontinued cholesterol medication, may boost brain-protective proteins in older adults at risk for dementia.
Small study tests psychedelic compound's safety and effectiveness against severe depression that doesn't respond to standard treatments.
Large 503-patient study tested whether Actovegin could improve thinking and memory problems that persist after stroke recovery.
